Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel
LON:PXS

Provexis Interim Earnings Report

GBX 1.25 +0.03 (+2.54%)
As of 12:32 PM Eastern
ProfileEarnings History

Provexis EPS Results

Actual EPS
-GBX 0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Provexis Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Provexis Announcement Details

Quarter
Interim
Date
12/31/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Provexis Earnings Headlines

AIM Market Roundup: Ramsdens, Provexis, Pulsar Helium
June 24, 2026  |  ca.finance.yahoo.comhttps://ca.finance.yahoo.com/news/aim-market-roundup-ramsdens-provexis-155328723.html
Provexis Secures Shareholder Support and Advances in Chinese Market
November 21, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/provexis-secures-shareholder-support-and-advances-in-chinese-market?utm_source=marketbeat.com&utm_medium=referral
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.tc pixel
August 17 at 1:00 AM  |  Altimetry (Ad)
AIM Market Roundup: Provexis, Geo Exploration, Sabien
November 19, 2025  |  sg.finance.yahoo.comhttps://sg.finance.yahoo.com/news/aim-market-roundup-provexis-geo-142747730.html
Provexis Faces Temporary Trading Suspension Amid Financial Reporting Delay
September 30, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/provexis-faces-temporary-trading-suspension-amid-financial-reporting-delay?utm_source=marketbeat.com&utm_medium=referral
Phase I trial finds topical PXS-6302 generally well tolerated in established skin scars
September 12, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/phase-i-trial-finds-topical-pxs-6302-generally-well-tolerated-in-established-skin-scars/ar-AA1MqHQg
See More Provexis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Provexis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Provexis and other key companies, straight to your email.

About Provexis

Provexis (LON:PXS), together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. Its products include Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke. The company's syrup and powder versions of Fruitflow are used in various foods, beverages, and dietary supplement formats. It offers Fruitflow + Omega-3, a supplement in capsule form that supports healthy blood flow and heart function. The company sells its products through distributors and online channels. Provexis plc was founded in 1999 and is based in Reading, the United Kingdom.

View Provexis Profile
Earnings Tools